• Je něco špatně v tomto záznamu ?

NAD(P)H:quinone oxidoreductase expression in Cyp1a-knockout and CYP1A-humanized mouse lines and its effect on bioactivation of the carcinogen aristolochic acid I

K. Levova, M. Moserova, DW. Nebert, DH. Phillips, E. Frei, HH. Schmeiser, VM. Arlt, M. Stiborova,

. 2012 ; 265 (3) : 360-7.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13024305

Aristolochic acid causes a specific nephropathy (AAN), Balkan endemic nephropathy, and urothelial malignancies. Using Western blotting suitable to determine protein expression, we investigated in several transgenic mouse lines expression of NAD(P)H:quinone oxidoreductase (NQO1)-the most efficient cytosolic enzyme that reductively activates aristolochic acid I (AAI). The mouse tissues used were from previous studies [Arlt et al., Chem. Res. Toxicol. 24 (2011) 1710; Stiborova et al., Toxicol. Sci. 125 (2012) 345], in which the role of microsomal cytochrome P450 (CYP) enzymes in AAI metabolism in vivo had been determined. We found that NQO1 levels in liver, kidney and lung of Cyp1a1⁻/⁻, Cyp1a2⁻/⁻ and Cyp1a1/1a2⁻/⁻ knockout mouse lines, as well as in two CYP1A-humanized mouse lines harboring functional human CYP1A1 and CYP1A2 and lacking the mouse Cyp1a1/1a2 orthologs, differed from NQO1 levels in wild-type mice. NQO1 protein and enzymic activity were induced in hepatic and renal cytosolic fractions isolated from AAI-pretreated mice, compared with those in untreated mice. Furthermore, this increase in hepatic NQO1 enzyme activity was associated with bioactivation of AAI and elevated AAI-DNA adduct levels in ex vivo incubations of cytosolic fractions with DNA and AAI. In conclusion, AAI appears to increase its own metabolic activation by inducing NQO1, thereby enhancing its own genotoxic potential.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13024305
003      
CZ-PrNML
005      
20171215201510.0
007      
ta
008      
130703s2012 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.taap.2012.09.004 $2 doi
035    __
$a (PubMed)22982977
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Levova, Katerina $u Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic.
245    10
$a NAD(P)H:quinone oxidoreductase expression in Cyp1a-knockout and CYP1A-humanized mouse lines and its effect on bioactivation of the carcinogen aristolochic acid I / $c K. Levova, M. Moserova, DW. Nebert, DH. Phillips, E. Frei, HH. Schmeiser, VM. Arlt, M. Stiborova,
520    9_
$a Aristolochic acid causes a specific nephropathy (AAN), Balkan endemic nephropathy, and urothelial malignancies. Using Western blotting suitable to determine protein expression, we investigated in several transgenic mouse lines expression of NAD(P)H:quinone oxidoreductase (NQO1)-the most efficient cytosolic enzyme that reductively activates aristolochic acid I (AAI). The mouse tissues used were from previous studies [Arlt et al., Chem. Res. Toxicol. 24 (2011) 1710; Stiborova et al., Toxicol. Sci. 125 (2012) 345], in which the role of microsomal cytochrome P450 (CYP) enzymes in AAI metabolism in vivo had been determined. We found that NQO1 levels in liver, kidney and lung of Cyp1a1⁻/⁻, Cyp1a2⁻/⁻ and Cyp1a1/1a2⁻/⁻ knockout mouse lines, as well as in two CYP1A-humanized mouse lines harboring functional human CYP1A1 and CYP1A2 and lacking the mouse Cyp1a1/1a2 orthologs, differed from NQO1 levels in wild-type mice. NQO1 protein and enzymic activity were induced in hepatic and renal cytosolic fractions isolated from AAI-pretreated mice, compared with those in untreated mice. Furthermore, this increase in hepatic NQO1 enzyme activity was associated with bioactivation of AAI and elevated AAI-DNA adduct levels in ex vivo incubations of cytosolic fractions with DNA and AAI. In conclusion, AAI appears to increase its own metabolic activation by inducing NQO1, thereby enhancing its own genotoxic potential.
650    _2
$a zvířata $7 D000818
650    _2
$a kyseliny aristolochové $x farmakokinetika $x toxicita $7 D034341
650    _2
$a balkánská nefropatie $x enzymologie $x genetika $x metabolismus $7 D001449
650    _2
$a western blotting $7 D015153
650    _2
$a buněčné linie $7 D002460
650    _2
$a cytochrom P-450 CYP1A1 $x nedostatek $x genetika $x metabolismus $7 D019363
650    _2
$a cytochrom P-450 CYP1A2 $x nedostatek $x genetika $x metabolismus $7 D019388
650    _2
$a cytosol $x enzymologie $x metabolismus $7 D003600
650    _2
$a adukty DNA $x metabolismus $7 D018736
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a játra $x účinky léků $x enzymologie $x metabolismus $7 D008099
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a myši knockoutované $7 D018345
650    _2
$a myši transgenní $7 D008822
650    _2
$a NAD(P)H dehydrogenasa (chinon) $x biosyntéza $x metabolismus $7 D016660
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Moserova, Michaela $u -
700    1_
$a Nebert, Daniel W $u -
700    1_
$a Phillips, David H $u -
700    1_
$a Frei, Eva $u -
700    1_
$a Schmeiser, Heinz H $u -
700    1_
$a Arlt, Volker M. $u - $7 xx0074763 $4
700    1_
$a Stiborova, Marie $u -
773    0_
$w MED00010691 $t Toxicology and applied pharmacology $x 1096-0333 $g Roč. 265, č. 3 (2012), s. 360-7
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22982977 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130703 $b ABA008
991    __
$a 20130709094837 $b ABA008
999    __
$a ok $b bmc $g 987985 $s 822685
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 265 $c 3 $d 360-7 $i 1096-0333 $m Toxicology and applied pharmacology $n Toxicol Appl Pharmacol $x MED00010691
LZP    __
$a Pubmed-20130703

Najít záznam

Citační ukazatele

Možnosti archivace